CHMP konkluderede derfor den 19. juli 2007, at benefit/ risk- forholdet for lægemidler indeholdende veraliprid ikke er gunstigt under normale anvendelsesbetingelser.
The CHMP therefore concluded on 19 July 2007 that the benefit/ risk balance of veralipride containing medicinal products is not positive under normal conditions of use.